Your essential biotech, medtech, and pharma recap — no noise, just what matters.

Monday, October 26, 2026

⚡ Executive Takeaway

The market put three prices on data this week, and they do not reconcile. A company with no readout until 2027 got the richest IPO debut of the cohort. A company holding a positive Phase 3 on the year's most watched readout lost a sixth of its value in a session, because the number landed at the bottom of what the run up had already priced. And the weekend supplied a third category: results that do not merely win their trials but rewrite a standard of care, a survival doubling in small cell lung cancer and the first head to head victory inside the KRAS class.

Monday's open is the experiment: Amgen, AstraZeneca, Roche and Summit all meet the tape at once, carrying exactly that kind of data. If the rewriters clear higher while the mere winners clear lower, the week's through line is set: only new standards get paid. Winning is table stakes now; the premium belongs to data that makes someone else's franchise obsolete.

🫁 Small Cell Lung Cancer Gets Its Rewrite

Tarlatamab moved to the front line and doubled the bar: a 58% cut in the risk of death as first line maintenance, with survival numbers the disease has never produced in Phase 3. AMGN | AZN

🧬 The First KRAS Head to Head Has a Winner

Divarasib extended median survival to 17.7 months against 12.0 for the two approved KRAS G12C drugs pooled, the hardest form of competitive evidence a class can produce. RHHBY | AMGN | BMY | LLY

Krascendo 1 put Roche's inhibitor directly against sotorasib and adagrasib in 338 previously treated KRAS G12C lung cancer patients and won on every line: a 0.56 hazard ratio for death, progression free survival of 9.8 versus 5.7 months, a 58% versus 32% response rate, and fewer serious treatment related adverse events (7.8% versus 15.2%), with simultaneous New England Journal of Medicine publication. Head to head trials inside a drug class almost never run because losing is existential; Roche ran one from behind and now holds the only overall survival superiority claim in the class. The company says it is working with health authorities and gave no submission date, while first line and adjuvant Phase 3 trials continue, and Eli Lilly presented durable first line data for its own challenger, olomorasib, on Sunday. Monday is the first reaction session; Friday's US close for Roche was 61.17, an ADR.

💉 The Vaccine That Won and Lost Anyway

Intismeran autogene met both endpoints of its Phase 3 melanoma trial, and Moderna still fell 17.6% in a session, because 42% sat at the bottom of what the run up had priced. MRNA | MRK

The leak crossed Thursday, after screenshots of the ESMO data surfaced on social media and the congress released the detailed findings two days early; it broke too late for Friday's edition and we are catching it up here, dated. The numbers themselves, per BioPharma Dive and Fierce Biotech from the presentation: recurrence free survival of 82.2% versus 70% at 24 months with Keytruda (a 42% risk reduction), distant metastasis free survival of 88.5% versus 80.2% (38%), in 1,137 resected stage IIB to IV melanoma patients. The Phase 2 figure at five years was 49%, analysts wanted 40% to 50%, and Moderna had roughly quadrupled since August's topline, so a win at the low end traded like a miss: down 17.6% Thursday on settled closes, another 1.2% Friday. Merck, which slipped about 3% across the two sessions, says it is preparing a US filing and hopes for an approval next year, per Fierce.

🔬 ESMO's Other Verdicts

A Chinese bispecific beat an approved immunotherapy in biliary tract cancer, prostate cancer produced three wins in one weekend, and Zentalis paid for a short duration number. SMMT | JNJ | ZNTL

Akeso's HARMONi-GI1 made ivonescimab plus chemotherapy the first regimen to beat an approved immunotherapy combination on overall survival in first line biliary tract cancer: 14.9 versus 12.1 months against durvalumab plus chemotherapy (hazard ratio 0.75) in a 682 patient trial run entirely in China by Akeso, which generated and analyzed the data. Partner Summit Therapeutics announced the result Sunday, three weeks before the FDA's November 14 decision on ivonescimab in lung cancer, with a US registration study already announced alongside ECOG-ACRIN.

Johnson & Johnson's prostate weekend ran from first in class to late stage: JNJ-6143, the first RIPTAC molecule in the clinic, produced confirmed responses in 12 of 16 patients with measurable disease at the 50 mg dose, an early Phase 1 figure with 5.6 months of follow up and every caveat that implies, while perioperative Erleada cut recurrence or death risk 62% in high risk localized disease and Bayer's Nubeqa cut metastasis or death risk 58% alongside hormone therapy and radiation. AstraZeneca's CLDN18.2 antibody drug conjugate sonesitatug vedotin cut the risk of death 42% in later line gastric cancer but missed its primary progression endpoint, a split regulators will have to parse. And Zentalis delivered the response detail its survival release had omitted: a 37.2% response rate with 5.5 months median duration in Cyclin E1 positive platinum resistant ovarian cancer, figures its executives confirmed to Fierce Biotech. The market read the duration as the headline and marked the stock down 8.3% Friday.

🩺 Diagnostics Had a Week

Labcorp bought again, Quest disclosed a breach, and Edwards opened the tricuspid repair market, most of it crossing midweek while attention was on Madrid. LH | DGX | EW | QGEN

Labcorp's $210 million purchase of Myriad Genetics' prenatal testing business, announced Tuesday per MedTech Dive, brings the FirstGene, Prequel, Foresight and SneakPeek tests and about $160 million in expected first year revenue, at 1.3 times revenue against the 2.9 times Labcorp paid for BioReference's assets the week before. Quest Diagnostics told the SEC on Wednesday that an unauthorized party accessed patient records through its Quanum test ordering and results system, scope undetermined, core operations unaffected; it joins Stryker, Boston Scientific, Medtronic, Abbott and Intuitive on the year's breach list, with Boston Scientific due to quantify its own attack on Wednesday's call. Edwards won FDA approval for Pascal Precision in tricuspid regurgitation, making it the only US provider of both transcatheter repair and replacement for the valve. And QIAGEN closed Friday at 50.39, pinned to the EQT offer, a second orderly week for the year's biggest diagnostics take private.

💰 Capital Keeps Paying for Stories

Lycia's debut closed 66.7% above the offer on the least clinical data in the cohort, while Zai Lab's buyers spent Friday endorsing the placement they priced into a policy wall. LYCA | ZLAB

Lycia Therapeutics sold 17,640,000 shares at $18.00 for $317.52 million gross, upsized, and closed its first Nasdaq session at 30.00; its LYTAC extracellular degraders produce no clinical readout until 2027, which under the two ended market rule is precisely why the premium is available, since data that does not exist cannot disappoint. The rest of the cohort held its shape: City 15.4% above its offer, Retension 27.1% above, Iambic 10.9% below with its dataset catalyst approaching, and Arcus's discounted paper 5.9% above its $17.50 clearing price. Zai Lab rose 9.0% to 24.03, above the $22.04 placement price, the first session's endorsement of Thursday night's $250 million raise ahead of an on or about Monday close. Bolt Biotherapeutics struck a reverse merger with Prana Therapies plus a $120 million placement, expandable to $180 million with warrants, per Fierce Biotech, and Star Therapeutics added $200 million, per BioPharma Dive.

📋 Quick Hits

Be sure to read the full article for all the details, including:

👉 Read the full breakdown →

📋 The Week in Review